Has Ron Bahar received payments from drug or device companies?

Yes. Drug and device makers reported $3,143 in general payments to Ron Bahar across 134 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Ron Bahar did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Ron Bahar come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Ron Bahar

Pediatric Gastroenterology · Encino, CANPI 1750479002

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 96.8% of the total across 134 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 21 manufacturers reported payments, led by AbbVie at 27.0% of the total.

$3,143in general payments, 2019–2025

Across 134 payments — averaging $23.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AbbVie$848
Regeneron Healthcare Solutions, Inc.$590
Sanofi$575
Johnson & Johnson$232
Novo Nordisk$146
Biohaven Pharmaceuticals, Inc.$124
plus $627 from 15 others

What the payments were for

Food & beverage$3,04497%
Education$1003%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AbbVie	49	$848
Regeneron Healthcare Solutions, Inc.	28	$590
Sanofi	24	$575
Johnson & Johnson(2 entities)	7	$232
Novo Nordisk	2	$146
Biohaven Pharmaceuticals, Inc.	1	$124
Novartis	1	$122
Romark Laboratories, LC	1	$101
Takeda Pharmaceuticals U.S.A., Inc.	2	$64
Capsovision, Inc.	3	$62
QOL Medical, LLC	3	$43
Pfizer	2	$39
Phadia US Inc.	2	$35
Concordia Pharmaceuticals Inc.	2	$34
Sandoz	1	$29
Ironwood Pharmaceuticals, Inc	1	$23
Nestle Healthcare Nutrition Inc.	1	$20
Albireo Pharma, Inc.	1	$19
Mirum Pharmaceuticals, Inc.	1	$19
Janssen Scientific Affairs, LLC	1	$16
Travere Therapeutics, Inc.	1	$1

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,143 in reported general payments places this provider in the 75th percentile of 220 pediatric gastroenterology providers in California.

See all pediatric gastroenterology providers in California →

Other pediatric gastroenterology in Encino

Brynie CollinsEncino$2K
David ZiringLos Angeles$206K
Nathan MinkoffMadera$131K
Paul HarmatzOakland$109K
Robert VenickLos Angeles$78K
Jessica DeasLos Angeles$74K
Amber HildrethSan Diego$67K
Ariel FeldsteinSan Diego$60K
Kathleen SchwarzSan Diego$58K
Andrew DickersonSan Diego$58K

See the full list for California →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →